crisaborole vs Roflumilast (Zoryve)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: PDE4 · full Atopic Dermatitis pipeline

crisaborole · Eucrisa

Marketed by Pfizer

Approved in Atopic Dermatitissmall molecule
Reliable signal

NCT02118792 · Phase 3 · completed

This was a randomized, quadruple-blind, vehicle-controlled trial with 763 participants. Its clinical primary efficacy endpoint—clear or almost clear skin with at least a two-grade improvement at Day 29—was met, with 31.4% success on crisaborole versus 18.0% on vehicle (p<0.001).

Next expected readout: January 2027 · NCT07162896 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29; Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs) (AEs: Baseline (Day 1) up to Day 29, SAEs: Baseline (Day 1) up to Day 36); Number of Participants With Clinically Significant Change From Baseline in Vital Signs at Day 29 (Baseline, Day 29); Number of Participants With Clinically Significant Change From Baseline in Laboratory Values at Day 29 (Baseline, Day 29): Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29 (Day 29): AN2728 Topical Ointment, 2 Percent 32.8% vs AN2728 Topical Ointment, Vehicle 25.4% (met)

Result source: NCT02118766

Roflumilast (Zoryve)

Marketed by Arcutis Biotherapeutics and partners

Approved in Atopic Dermatitissmall molecule
Reliable signal

NCT06631170 · Phase 3 · completed

The trial was randomized, fully blinded, and vehicle-controlled with a validated disease-severity measure as its primary endpoint, and roflumilast cream produced significantly more treatment successes than vehicle (31.9% vs 6.7%, P<0.0001).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: August 2027 · NCT07560618 (registry estimate)

Reported efficacy

Percentage of subjects with vIGA-AD success (Baseline, week 4): Primary endpoint, Week 4 IGA (vIGA-AD) treatment-success rate: 31.9% with 0.15% roflumilast cream vs 6.7% with vehicle (P<0.0001) (met)

Result source: NCT06631170

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointcrisaboroleRoflumilast (Zoryve)
EASI-7546.4% vs 27.6%+18.8 vs placebo2% twice a day · wk 4.14 · n 260NCT04360187
3 other results
  • 38.2% vs 26.3% 2% twice a day · wk 3.14 · n 260 · Phase 3 · secondary NCT04360187
  • 26.3% vs 15.4% 2% twice a day · wk 2.14 · n 260 · Phase 3 · secondary NCT04360187
  • 11.2% vs 6.1% 2% twice a day · wk 1.14 · n 260 · Phase 3 · secondary NCT04360187
43.2% vs 22%+21.2 vs placebo0.15% cream · wk 4 · n 433NCT04773587
8 other results
  • 42% vs 19.7% 0.15% cream · wk 4 · n 451 · Phase 3 · secondary NCT04773600
  • 39.4% vs 20.6% 0.05% cream · wk 4 · n 436 · Phase 3 · secondary NCT04845620
  • 56.5% vs 31.1% 0.05% · wk 4 · n 46 · Phase 2 · secondary NCT03916081
  • 51.1% vs 31.1% 0.15% · wk 4 · n 45 · Phase 2 · secondary NCT03916081
  • 17.4% vs 24.4% 0.05% · wk 2 · n 46 · Phase 2 · secondary NCT03916081
  • 31.1% vs 24.4% 0.15% · wk 2 · n 45 · Phase 2 · secondary NCT03916081
  • 8.7% vs 2.2% 0.05% · wk 1 · n 46 · Phase 2 · secondary NCT03916081
  • 13.3% vs 2.2% 0.15% · wk 1 · n 45 · Phase 2 · secondary NCT03916081
IGA 0/1 with 2-point improvement—Trial running · NCT07162896—Not posted · NCT06631170
EASI-90—Trial running · NCT0716289617.4% vs 17.8%−0.4 vs placebo0.05% · wk 4 · n 46NCT03916081
5 other results
  • 26.7% vs 17.8% 0.15% · wk 4 · n 45 · Phase 2 · secondary NCT03916081
  • 2.2% vs 8.9% 0.05% · wk 2 · n 46 · Phase 2 · secondary NCT03916081
  • 13.3% vs 8.9% 0.15% · wk 2 · n 45 · Phase 2 · secondary NCT03916081
  • 0% vs 0% 0.05% · wk 1 · n 46 · Phase 2 · secondary NCT03916081
  • 2.2% vs 0% 0.15% · wk 1 · n 45 · Phase 2 · secondary NCT03916081
EASI, % change-59.9% vs -42.8%−17.1 vs placebo2% twice a day · wk 4 · n 260NCT04360187
41 other results
  • -10.2% vs 2.9% 2% QD · wk 4 · n 125 · Phase 3 · secondary NCT04040192
  • 407.5% vs 2.9% 2% BID · wk 4 · n 175 · Phase 3 · secondary NCT04040192
  • -10.3% vs -0.5% 2% QD · wk 4 · n 125 · Phase 3 · secondary NCT04040192
  • -59.9% vs -42.8% 2% twice a day · wk 4.14 · n 260 · Phase 3 · secondary NCT04360187
  • -55.0% vs -42.9% 2% twice a day · wk 3.14 · n 260 · Phase 3 · secondary NCT04360187
  • -49.6% vs -37.1% 2% twice a day · wk 2.14 · n 260 · Phase 3 · secondary NCT04360187
  • -36.6% vs -21.4% 2% twice a day · wk 1.14 · n 260 · Phase 3 · secondary NCT04360187
  • 34.3% vs 1.0% 2% QD · wk 8 · n 125 · Phase 3 · secondary NCT04040192
  • 239.9% vs 1.0% 2% BID · wk 8 · n 175 · Phase 3 · secondary NCT04040192
  • 10.4% vs -21.3% 2% QD · wk 8 · n 125 · Phase 3 · secondary NCT04040192
  • -8.2% vs -0.1% 2% QD · wk 12 · n 125 · Phase 3 · secondary NCT04040192
  • 401.4% vs -0.1% 2% BID · wk 12 · n 175 · Phase 3 · secondary NCT04040192
  • -9.4% vs 2.2% 2% QD · wk 12 · n 125 · Phase 3 · secondary NCT04040192
  • 28.0% vs 26.3% 2% QD · wk 16 · n 125 · Phase 3 · secondary NCT04040192
  • 272.9% vs 26.3% 2% BID · wk 16 · n 175 · Phase 3 · secondary NCT04040192
  • -0.5% vs -14.8% 2% QD · wk 16 · n 125 · Phase 3 · secondary NCT04040192
  • -45.4% vs 26.4% 2% QD · wk 20 · n 125 · Phase 3 · secondary NCT04040192
  • 264.7% vs 26.4% 2% BID · wk 20 · n 175 · Phase 3 · secondary NCT04040192
  • -74.3% vs 200% 2% QD · wk 20 · n 125 · Phase 3 · secondary NCT04040192
  • 6.9% vs -20.6% 2% QD · wk 24 · n 125 · Phase 3 · secondary NCT04040192
  • 270.2% vs -20.6% 2% BID · wk 24 · n 175 · Phase 3 · secondary NCT04040192
  • -10.8% vs -35.6% 2% QD · wk 24 · n 125 · Phase 3 · secondary NCT04040192
  • -33.0% vs 19.2% 2% QD · wk 28 · n 125 · Phase 3 · secondary NCT04040192
  • 454.0% vs 19.2% 2% BID · wk 28 · n 175 · Phase 3 · secondary NCT04040192
  • -34.5% vs 0% 2% QD · wk 28 · n 125 · Phase 3 · secondary NCT04040192
  • -19.3% vs 13.6% 2% QD · wk 32 · n 125 · Phase 3 · secondary NCT04040192
  • 341.2% vs 13.6% 2% BID · wk 32 · n 175 · Phase 3 · secondary NCT04040192
  • -27.8% vs -28.4% 2% QD · wk 32 · n 125 · Phase 3 · secondary NCT04040192
  • 211.1% vs -56.0% 2% QD · wk 36 · n 125 · Phase 3 · secondary NCT04040192
  • 184.3% vs -56.0% 2% BID · wk 36 · n 175 · Phase 3 · secondary NCT04040192
  • -12.9% vs 10% 2% QD · wk 40 · n 125 · Phase 3 · secondary NCT04040192
  • 330.8% vs 10% 2% BID · wk 40 · n 175 · Phase 3 · secondary NCT04040192
  • -47.6% vs 2.2% 2% QD · wk 40 · n 125 · Phase 3 · secondary NCT04040192
  • 127.6% vs -59.7% 2% QD · wk 44 · n 125 · Phase 3 · secondary NCT04040192
  • 444% vs -59.7% 2% BID · wk 44 · n 175 · Phase 3 · secondary NCT04040192
  • -30.0% vs -22.2% 2% QD · wk 48 · n 125 · Phase 3 · secondary NCT04040192
  • 390.3% vs -22.2% 2% BID · wk 48 · n 175 · Phase 3 · secondary NCT04040192
  • -39.1% vs -27.3% 2% QD · wk 48 · n 125 · Phase 3 · secondary NCT04040192
  • -49.8% vs -39.3% 2% QD · wk 52 · n 125 · Phase 3 · secondary NCT04040192
  • 250.1% vs -39.3% 2% BID · wk 52 · n 175 · Phase 3 · secondary NCT04040192
  • -59.9% vs -54.3% 2% QD · wk 52 · n 125 · Phase 3 · secondary NCT04040192
-69.4% vs -55.8%−13.5 vs placebo0.05% · wk 4 · n 46NCT03916081
5 other results
  • -72.3% vs -55.8% 0.15% · wk 4 · n 45 · Phase 2 · secondary NCT03916081
  • -54.3% vs -48.5% 0.05% · wk 2 · n 46 · Phase 2 · secondary NCT03916081
  • -57.6% vs -48.5% 0.15% · wk 2 · n 45 · Phase 2 · secondary NCT03916081
  • -35.8% vs -24.4% 0.05% · wk 1 · n 46 · Phase 2 · secondary NCT03916081
  • -34.7% vs -24.4% 0.15% · wk 1 · n 45 · Phase 2 · secondary NCT03916081

EASI-75

crisaborole
46.4% vs 27.6%+18.8 vs placebo2% twice a day · wk 4.14 · n 260NCT04360187
3 other results
  • 38.2% vs 26.3% 2% twice a day · wk 3.14 · n 260 · Phase 3 · secondary NCT04360187
  • 26.3% vs 15.4% 2% twice a day · wk 2.14 · n 260 · Phase 3 · secondary NCT04360187
  • 11.2% vs 6.1% 2% twice a day · wk 1.14 · n 260 · Phase 3 · secondary NCT04360187
Roflumilast (Zoryve)
43.2% vs 22%+21.2 vs placebo0.15% cream · wk 4 · n 433NCT04773587
8 other results
  • 42% vs 19.7% 0.15% cream · wk 4 · n 451 · Phase 3 · secondary NCT04773600
  • 39.4% vs 20.6% 0.05% cream · wk 4 · n 436 · Phase 3 · secondary NCT04845620
  • 56.5% vs 31.1% 0.05% · wk 4 · n 46 · Phase 2 · secondary NCT03916081
  • 51.1% vs 31.1% 0.15% · wk 4 · n 45 · Phase 2 · secondary NCT03916081
  • 17.4% vs 24.4% 0.05% · wk 2 · n 46 · Phase 2 · secondary NCT03916081
  • 31.1% vs 24.4% 0.15% · wk 2 · n 45 · Phase 2 · secondary NCT03916081
  • 8.7% vs 2.2% 0.05% · wk 1 · n 46 · Phase 2 · secondary NCT03916081
  • 13.3% vs 2.2% 0.15% · wk 1 · n 45 · Phase 2 · secondary NCT03916081

IGA 0/1 with 2-point improvement

crisaborole
—Trial running · NCT07162896
Roflumilast (Zoryve)
—Not posted · NCT06631170

EASI-90

crisaborole
—Trial running · NCT07162896
Roflumilast (Zoryve)
17.4% vs 17.8%−0.4 vs placebo0.05% · wk 4 · n 46NCT03916081
5 other results
  • 26.7% vs 17.8% 0.15% · wk 4 · n 45 · Phase 2 · secondary NCT03916081
  • 2.2% vs 8.9% 0.05% · wk 2 · n 46 · Phase 2 · secondary NCT03916081
  • 13.3% vs 8.9% 0.15% · wk 2 · n 45 · Phase 2 · secondary NCT03916081
  • 0% vs 0% 0.05% · wk 1 · n 46 · Phase 2 · secondary NCT03916081
  • 2.2% vs 0% 0.15% · wk 1 · n 45 · Phase 2 · secondary NCT03916081

EASI, % change

crisaborole
-59.9% vs -42.8%−17.1 vs placebo2% twice a day · wk 4 · n 260NCT04360187
41 other results
  • -10.2% vs 2.9% 2% QD · wk 4 · n 125 · Phase 3 · secondary NCT04040192
  • 407.5% vs 2.9% 2% BID · wk 4 · n 175 · Phase 3 · secondary NCT04040192
  • -10.3% vs -0.5% 2% QD · wk 4 · n 125 · Phase 3 · secondary NCT04040192
  • -59.9% vs -42.8% 2% twice a day · wk 4.14 · n 260 · Phase 3 · secondary NCT04360187
  • -55.0% vs -42.9% 2% twice a day · wk 3.14 · n 260 · Phase 3 · secondary NCT04360187
  • -49.6% vs -37.1% 2% twice a day · wk 2.14 · n 260 · Phase 3 · secondary NCT04360187
  • -36.6% vs -21.4% 2% twice a day · wk 1.14 · n 260 · Phase 3 · secondary NCT04360187
  • 34.3% vs 1.0% 2% QD · wk 8 · n 125 · Phase 3 · secondary NCT04040192
  • 239.9% vs 1.0% 2% BID · wk 8 · n 175 · Phase 3 · secondary NCT04040192
  • 10.4% vs -21.3% 2% QD · wk 8 · n 125 · Phase 3 · secondary NCT04040192
  • -8.2% vs -0.1% 2% QD · wk 12 · n 125 · Phase 3 · secondary NCT04040192
  • 401.4% vs -0.1% 2% BID · wk 12 · n 175 · Phase 3 · secondary NCT04040192
  • -9.4% vs 2.2% 2% QD · wk 12 · n 125 · Phase 3 · secondary NCT04040192
  • 28.0% vs 26.3% 2% QD · wk 16 · n 125 · Phase 3 · secondary NCT04040192
  • 272.9% vs 26.3% 2% BID · wk 16 · n 175 · Phase 3 · secondary NCT04040192
  • -0.5% vs -14.8% 2% QD · wk 16 · n 125 · Phase 3 · secondary NCT04040192
  • -45.4% vs 26.4% 2% QD · wk 20 · n 125 · Phase 3 · secondary NCT04040192
  • 264.7% vs 26.4% 2% BID · wk 20 · n 175 · Phase 3 · secondary NCT04040192
  • -74.3% vs 200% 2% QD · wk 20 · n 125 · Phase 3 · secondary NCT04040192
  • 6.9% vs -20.6% 2% QD · wk 24 · n 125 · Phase 3 · secondary NCT04040192
  • 270.2% vs -20.6% 2% BID · wk 24 · n 175 · Phase 3 · secondary NCT04040192
  • -10.8% vs -35.6% 2% QD · wk 24 · n 125 · Phase 3 · secondary NCT04040192
  • -33.0% vs 19.2% 2% QD · wk 28 · n 125 · Phase 3 · secondary NCT04040192
  • 454.0% vs 19.2% 2% BID · wk 28 · n 175 · Phase 3 · secondary NCT04040192
  • -34.5% vs 0% 2% QD · wk 28 · n 125 · Phase 3 · secondary NCT04040192
  • -19.3% vs 13.6% 2% QD · wk 32 · n 125 · Phase 3 · secondary NCT04040192
  • 341.2% vs 13.6% 2% BID · wk 32 · n 175 · Phase 3 · secondary NCT04040192
  • -27.8% vs -28.4% 2% QD · wk 32 · n 125 · Phase 3 · secondary NCT04040192
  • 211.1% vs -56.0% 2% QD · wk 36 · n 125 · Phase 3 · secondary NCT04040192
  • 184.3% vs -56.0% 2% BID · wk 36 · n 175 · Phase 3 · secondary NCT04040192
  • -12.9% vs 10% 2% QD · wk 40 · n 125 · Phase 3 · secondary NCT04040192
  • 330.8% vs 10% 2% BID · wk 40 · n 175 · Phase 3 · secondary NCT04040192
  • -47.6% vs 2.2% 2% QD · wk 40 · n 125 · Phase 3 · secondary NCT04040192
  • 127.6% vs -59.7% 2% QD · wk 44 · n 125 · Phase 3 · secondary NCT04040192
  • 444% vs -59.7% 2% BID · wk 44 · n 175 · Phase 3 · secondary NCT04040192
  • -30.0% vs -22.2% 2% QD · wk 48 · n 125 · Phase 3 · secondary NCT04040192
  • 390.3% vs -22.2% 2% BID · wk 48 · n 175 · Phase 3 · secondary NCT04040192
  • -39.1% vs -27.3% 2% QD · wk 48 · n 125 · Phase 3 · secondary NCT04040192
  • -49.8% vs -39.3% 2% QD · wk 52 · n 125 · Phase 3 · secondary NCT04040192
  • 250.1% vs -39.3% 2% BID · wk 52 · n 175 · Phase 3 · secondary NCT04040192
  • -59.9% vs -54.3% 2% QD · wk 52 · n 125 · Phase 3 · secondary NCT04040192
Roflumilast (Zoryve)
-69.4% vs -55.8%−13.5 vs placebo0.05% · wk 4 · n 46NCT03916081
5 other results
  • -72.3% vs -55.8% 0.15% · wk 4 · n 45 · Phase 2 · secondary NCT03916081
  • -54.3% vs -48.5% 0.05% · wk 2 · n 46 · Phase 2 · secondary NCT03916081
  • -57.6% vs -48.5% 0.15% · wk 2 · n 45 · Phase 2 · secondary NCT03916081
  • -35.8% vs -24.4% 0.05% · wk 1 · n 46 · Phase 2 · secondary NCT03916081
  • -34.7% vs -24.4% 0.15% · wk 1 · n 45 · Phase 2 · secondary NCT03916081
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. crisaborole: 7 of 7 rows · Roflumilast (Zoryve): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriccrisaborole
Rows use multiple source trials
Roflumilast (Zoryve)
Rows use multiple source trials
BSA
absolute change · percentage points
6.25% (n=175) vs 1.16% (n=129) placebo @ 4wk2% BIDa,b,c,d
NCT04040192 · Phase 3 · registry result, not featured evidence
show 3 more doses
0.52% (n=125) vs 1.16% (n=129) placebo @ 4wk2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
0.53% (n=125) vs 1.2% (n=129) placebo @ 4wk2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
4.17% (n=81) vs 6.92% (n=96) placebo @ 4wk2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
-4.41% (n=46) vs -4.16% (n=45) placebo @ 4wk0.05%a,b,c,d
NCT03916081 · Phase 2 · registry result, not featured evidence
show 1 more dose
-5.1% (n=45) vs -4.16% (n=45) placebo @ 4wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
EASI-50
responder rate · % of participants
72.7% (n=260) vs 49.4% (n=131) placebo @ 4.14wk2% twice a dayb,c,d,e
NCT04360187 · Phase 3 · registry result, not featured evidence
69.6% (n=46) vs 55.6% (n=45) placebo @ 4wk*0.05%a,b,c,d,e
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted
show 1 more dose
73.3% (n=45) vs 55.6% (n=45) placebo @ 4wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 33 Participants as posted
SCORAD
absolute change · score
25.78 vs 17.2 placebo score @ 12.8571wkf,c,d,g
NCT03832010 · Phase 4 · registry result, not featured evidence
-2.3 vs -1.75 placebo score @ 2.142857wk0.5%f,c,d,g
NCT01856764 · Phase 2 · registry result, not featured evidence
Dropout rate
6%2% ointmenth
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 22 more results
—2% ointment
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
5.9%2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
—2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
50%
NCT03832010 · Phase 4 · registry result, not featured evidence
3.6%2%
NCT03356977 · Phase 4 · registry result, not featured evidence
—2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
—2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
—2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
—2% BID
NCT04040192 · Phase 3 · registry result, not featured evidence
5.8%2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
0%2% QD
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
0%2% BID
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
0%2% BID
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
0%2% QD
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
—
NCT03233529 · Phase 2 · registry result, not featured evidence
0%0.5% + 2% once daily
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
2.4%0.5% + 2% twice daily
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
12%2%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
4.8%1%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
4.3%2 percent
NCT01652885 · Phase 1/2 · registry result, not featured evidence
0%Cohort 1: Crisaborole Ointment 2%
NCT03260595 · Phase 1 · registry result, not featured evidence
0%Cohort 2: Crisaborole Ointment 2%
NCT03260595 · Phase 1 · registry result, not featured evidence
6.7%0.15% creami
NCT04773587 · Phase 3
show 7 more results
9.1%0.15% cream
NCT04773600 · Phase 3
6.2%0.05% cream
NCT04845620 · Phase 3
34.2%0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
33.8%0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
8.7%0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence
2.2%0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
0%0.5%
NCT01856764 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1%2% ointmenth
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 22 more results
—2% ointment
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
1.4%2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
—2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
—
NCT03832010 · Phase 4 · registry result, not featured evidence
—2%
NCT03356977 · Phase 4 · registry result, not featured evidence
—2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
—2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
—2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
—2% BID
NCT04040192 · Phase 3 · registry result, not featured evidence
4.2%2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
—2% QD
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
—2% BID
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
—2% BID
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
—2% QD
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
—
NCT03233529 · Phase 2 · registry result, not featured evidence
0%0.5% + 2% once daily
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
2.4%0.5% + 2% twice daily
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
—2%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
—1%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
4.3%2 percent
NCT01652885 · Phase 1/2 · registry result, not featured evidence
—Cohort 1: Crisaborole Ointment 2%
NCT03260595 · Phase 1 · registry result, not featured evidence
—Cohort 2: Crisaborole Ointment 2%
NCT03260595 · Phase 1 · registry result, not featured evidence
1.4%0.15% creami
NCT04773587 · Phase 3
show 7 more results
1.8%0.15% cream
NCT04773600 · Phase 3
1.1%0.05% cream
NCT04845620 · Phase 3
2.3%0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
4.6%0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
2.2%0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence
0%0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
—0.5%
NCT01856764 · Phase 2 · registry result, not featured evidence
Serious AEs
—2% ointmenth
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 22 more results
0.6%2% ointment
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
—2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
1%2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
0%
NCT03832010 · Phase 4 · registry result, not featured evidence
0.7%2%
NCT03356977 · Phase 4 · registry result, not featured evidence
—2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
1.3%2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
1.5%2% QD
NCT04040192 · Phase 3 · registry result, not featured evidence
0.6%2% BID
NCT04040192 · Phase 3 · registry result, not featured evidence
0.4%2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
0%2% QD
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
0%2% BID
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
0%2% BID
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
0%2% QD
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
0%
NCT03233529 · Phase 2 · registry result, not featured evidence
0%0.5% + 2% once daily
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
0%0.5% + 2% twice daily
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
0%2%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
0%1%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
0%2 percent
NCT01652885 · Phase 1/2 · registry result, not featured evidence
0%Cohort 1: Crisaborole Ointment 2%
NCT03260595 · Phase 1 · registry result, not featured evidence
0%Cohort 2: Crisaborole Ointment 2%
NCT03260595 · Phase 1 · registry result, not featured evidence
0.9%0.15% creami
NCT04773587 · Phase 3
show 7 more results
0.9%0.15% cream
NCT04773600 · Phase 3
0.2%0.05% cream
NCT04845620 · Phase 3
1.1%0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
1.4%0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
2.2%0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence
0%0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
0%0.5%
NCT01856764 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
2% ointmenth
upper respiratory tract infection 3.1% (placebo 2%)
application site pain 2.7% (placebo 1.2%)
nasopharyngitis 1.8% (placebo 2.4%)
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 19 more results
2%
burning/stinging: mild 23.9% (placebo 19%)
burning/stinging: moderate 18.1% (placebo 17.1%)
burning/stinging: severe 8.2% (placebo 4%)
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
burning sensation after the first application of the assigned study medication. 12.5% (placebo 0%)
NCT03832010 · Phase 4 · registry result, not featured evidence
2%
pyrexia 9.5%
diarrhoea 7.3%
upper respiratory tract infection 7.3%
NCT03356977 · Phase 4 · registry result, not featured evidence
2% QD
dermatitis atopic 2.6% (placebo 2.2%)
application site acne 1.3% (placebo 0%)
application site infection 1.3% (placebo 3.4%)
NCT04040192 · Phase 3 · registry result, not featured evidence
2% QD
covid-19 3.7% (placebo 1.1%)
upper respiratory tract infection 3% (placebo 1.1%)
headache 2.2% (placebo 1.1%)
NCT04040192 · Phase 3 · registry result, not featured evidence
2% BID
application site pain 5.6% (placebo 1.1%)
dermatitis atopic 2.4% (placebo 2.2%)
upper respiratory tract infection 2% (placebo 1.1%)
NCT04040192 · Phase 3 · registry result, not featured evidence
2% twice a day
application site pain 13.1% (placebo 3.8%)
dermatitis atopic 7.7% (placebo 11.5%)
application site discolouration 3.5% (placebo 0.8%)
NCT04360187 · Phase 3 · registry result, not featured evidence
2% QD
application site irritation 15%
application site pruritus 15%
application site folliculitis 5%
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
2% BID
application site irritation 19%
oropharyngeal pain 14.3%
application site pruritus 9.5%
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
2% BID
application site pain 5%
application site pruritus 5%
hand-foot-and-mouth disease 5%
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
2% QD
arthralgia 5%
hand-foot-and-mouth disease 5%
application site coldness 0%
NCT03954158 · Phase 2 · registry result, not featured evidence · combination
dermatitis atopic 12.8%
nasopharyngitis 12.8%
application site pain 10.3%
NCT03233529 · Phase 2 · registry result, not featured evidence
0.5% + 2% once daily
application site pain 4.5%
application site pruritus 2.3%
asthma 2.3%
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
0.5% + 2% twice daily
nasopharyngitis 4.8%
application site pruritus 2.4%
arthralgia 2.4%
NCT01602341 · Phase 2 · registry result, not featured evidence · combination
2%
upper respiratory tract infection 24%
headache 8%
application site erythema 4%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
1%
upper respiratory tract infection 14.3%
application site cellulitis 4.8%
application site erythema 4.8%
NCT01301508 · Phase 2 · registry result, not featured evidence · combination
2 percent
application site pain 13%
nasopharyngitis 13%
dysmenorrhoea 5.3%
NCT01652885 · Phase 1/2 · registry result, not featured evidence
application site coldness 0% (placebo 50%)
application site irritation 0% (placebo 50%)
application site pain 0% (placebo 50%)
NCT03260595 · Phase 1 · registry result, not featured evidence
application site irritation 70% (placebo 50%)
application site pain 40% (placebo 50%)
application site coldness 10% (placebo 50%)
NCT03260595 · Phase 1 · registry result, not featured evidence
0.15%i
covid-19 4.1%
nasopharyngitis 2.7%
upper respiratory tract infection 2.1%
NCT04804605 · Phase 3 · registry result, not featured evidence
show 2 more results
0.15%
covid-19 5.5%
upper respiratory tract infection 5.5%
nasopharyngitis 3.7%
NCT04804605 · Phase 3 · registry result, not featured evidence
0.5%
nasopharyngitis 15% (placebo 0%)
alanine aminotransferase increased 5% (placebo 0%)
application site pain 5% (placebo 5%)
NCT01856764 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 4.14 weeks versus 4 weeks.
  6. fTrial phases differ: Phase 4 versus Phase 2.
  7. gAssessment timepoints differ: 12.8571 weeks versus 2.142857 weeks.
  8. hPopulation comparability has not been reviewed for 19 of these studies.
  9. iPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

crisaborole

ISGA Success 31.4% (n=513) vs 18% (n=250) placebo @ 4wk2% ointment
responder rate · % of participants
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 6 more results
32.8% (n=503) vs 25.4% (n=256) placebo @ 4.14wk2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
27.6% (n=260) vs 15.9% (n=131) placebo @ 4wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
4.8% (n=260) vs 0% (n=131) placebo @ 1.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
11.6% (n=260) vs 4.9% (n=131) placebo @ 2.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
18.1% (n=260) vs 10.8% (n=131) placebo @ 3.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
27.6% (n=260) vs 15.9% (n=131) placebo @ 4.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
ISGA 0/1 48.5% (n=513) vs 29.7% (n=250) placebo @ 4wk2% ointment
responder rate · % of participants
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 6 more results
51.7% (n=503) vs 40.6% (n=256) placebo @ 4.14wk2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
41.4% (n=260) vs 28.5% (n=131) placebo @ 4wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
16.8% (n=260) vs 7.8% (n=131) placebo @ 1.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
25.6% (n=260) vs 18.3% (n=131) placebo @ 2.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
32.3% (n=260) vs 25.1% (n=131) placebo @ 3.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
41.4% (n=260) vs 28.5% (n=131) placebo @ 4.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
Time to ISGA Success Median NA vs NA placebo months2% ointment
time to event · months
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 1 more result
NA vs NA placebo months2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
Erythema -0.7 vs -0.3 placebo score @ 4wk2% ointment
absolute change · score
Erythema: Change at Day 29 (n =486, 224)
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
Time to Pruritus Improvement Median 0.05 vs 0.05 placebo months2% ointment
time to event · months
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3 · converted to months from 1.41 days as posted
show 1 more result
0.04 vs 0.06 placebo months*2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3 · converted to months from 1.32 days as posted
CDLQI -4 vs -2.9 placebo score @ 4.14wk2% ointment
absolute change · score
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 4 more results
5 vs 3.17 placebo score @ 4.2857wk
NCT03832010 · Phase 4 · registry result, not featured evidence
5.75 vs 2 placebo score @ 12.8571wk
NCT03832010 · Phase 4 · registry result, not featured evidence
-3.6 vs -1.3 placebo score @ 2.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
-3.9 vs -1.8 placebo score @ 4.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
DLQI -5 vs -3.4 placebo score @ 4.14wk2% ointment
absolute change · score
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 3 more results
-5.5 vs -3.6 placebo score @ 4.14wk2%
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
-1.7 vs -1.1 placebo score @ 2.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
-1.8 vs -1.5 placebo score @ 4.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
DFI -3.6 vs -2.8 placebo score @ 4.14wk2% ointment
absolute change · score
NCT02118792 · Phase 3 · Atopic Dermatitis · phase 3
show 4 more results
7 vs 5.5 placebo score @ 4.2857wk
NCT03832010 · Phase 4 · registry result, not featured evidence
10.25 vs 2.6 placebo score @ 12.8571wk
NCT03832010 · Phase 4 · registry result, not featured evidence
-2.4 vs -0.5 placebo score @ 2.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
-3 vs -2.1 placebo score @ 4.14wk2% twice a day
NCT04360187 · Phase 3 · registry result, not featured evidence
Erythema -0.7 vs -0.4 placebo score @ 4wk2%
absolute change · score
Erythema: Change at Day 29 (n=478,228)
NCT02118766 · Phase 3 · Atopic Dermatitis · phase 3
Pruritus 5.2 vs 4.17 placebo score @ 4.2857wk
absolute change · score
NCT03832010 · Phase 4 · registry result, not featured evidence
show 15 more results
4 vs 2.8 placebo score @ 12.8571wk
NCT03832010 · Phase 4 · registry result, not featured evidence
-1.9 vs -1 placebo score @ 0.29wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-2.2 vs -0.9 placebo score @ 0.43wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-2.4 vs -1.1 placebo score @ 0.57wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-2.7 vs -1.1 placebo score @ 0.71wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-2.6 vs -1.3 placebo score @ 0.86wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.1 vs -1.5 placebo score @ 1wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.4 vs -1.5 placebo score @ 1.14wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.4 vs -1.5 placebo score @ 1.29wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.5 vs -1.6 placebo score @ 1.43wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.5 vs -2 placebo score @ 1.57wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.7 vs -1.5 placebo score @ 1.71wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-4 vs -2.2 placebo score @ 1.86wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.9 vs -2.2 placebo score @ 2wk
NCT03233529 · Phase 2 · registry result, not featured evidence
-3.9 vs -2 placebo score @ 2.14wk
NCT03233529 · Phase 2 · registry result, not featured evidence
Time to Flare 3.65 vs 0.99 placebo months @ 52wk2% QD
time to event · months
NCT04040192 · Phase 3 · registry result, not featured evidence · converted to months from 111 days as posted
Flare-Free 7.69 vs 6.55 placebo months @ 52wk2% QD
absolute value · months
NCT04040192 · Phase 3 · registry result, not featured evidence · converted to months from 234.01 days as posted

+ 30 further endpoints in the CSV export.

Roflumilast (Zoryve)

vIGA-AD 0 1 32% (n=433) vs 15.2% (n=221) placebo @ 4wk0.15% cream
responder rate · % of participants
NCT04773587 · Phase 3
show 17 more results
35% (n=328) vs 17.5% (n=164) placebo @ 4wk0.15% cream
NCT04773587 · Phase 3
21.2% (n=433) vs 6.4% (n=221) placebo @ 2wk0.15% cream
NCT04773587 · Phase 3
8.1% (n=433) vs 0.5% (n=221) placebo @ 1wk0.15% cream
NCT04773587 · Phase 3
28.9% (n=451) vs 12% (n=232) placebo @ 4wk0.15% cream
NCT04773600 · Phase 3
32.9% (n=342) vs 13.1% (n=179) placebo @ 4wk0.15% cream
NCT04773600 · Phase 3
17.7% (n=451) vs 5.3% (n=232) placebo @ 2wk0.15% cream
NCT04773600 · Phase 3
5.9% (n=451) vs 3.1% (n=232) placebo @ 1wk0.15% cream
NCT04773600 · Phase 3
39% (n=451) vs 16.9% (n=232) placebo @ 4wk0.15% cream
NCT04773600 · Phase 3
27.6% (n=451) vs 10.7% (n=232) placebo @ 2wk0.15% cream
NCT04773600 · Phase 3
14.2% (n=451) vs 6.2% (n=232) placebo @ 1wk0.15% cream
NCT04773600 · Phase 3
25.4% (n=436) vs 10.7% (n=215) placebo @ 4wk0.05% cream
NCT04845620 · Phase 3
27.7% (n=333) vs 11% (n=171) placebo @ 4wk0.05% cream
NCT04845620 · Phase 3
35.4% (n=436) vs 14.6% (n=215) placebo @ 4wk0.05% cream
NCT04845620 · Phase 3
21.2% (n=436) vs 6.8% (n=215) placebo @ 2wk0.05% cream
NCT04845620 · Phase 3
9.4% (n=436) vs 0.9% (n=215) placebo @ 1wk0.05% cream
NCT04845620 · Phase 3
30.4% (n=436) vs 10.6% (n=215) placebo @ 2wk0.05% cream
NCT04845620 · Phase 3
17% (n=436) vs 3.7% (n=215) placebo @ 1wk0.05% cream
NCT04845620 · Phase 3
WI-NRS 4-point Reduction 33.6% (n=278) vs 20.7% (n=135) placebo @ 4wk0.15% cream
responder rate · % of participants
NCT04773587 · Phase 3
show 5 more results
23.8% (n=278) vs 9.8% (n=135) placebo @ 2wk0.15% cream
NCT04773587 · Phase 3
9.5% (n=278) vs 2.3% (n=135) placebo @ 1wk0.15% cream
NCT04773587 · Phase 3
30.2% (n=264) vs 12.4% (n=136) placebo @ 4wk0.15% cream
NCT04773600 · Phase 3
22.3% (n=264) vs 6.9% (n=136) placebo @ 2wk0.15% cream
NCT04773600 · Phase 3
11.2% (n=264) vs 1.6% (n=136) placebo @ 1wk0.15% cream
NCT04773600 · Phase 3
IGA 0/1 41.5% (n=433) vs 25.2% (n=221) placebo @ 4wk0.15% cream
responder rate · % of participants
NCT04773587 · Phase 3
show 2 more results
31.8% (n=433) vs 13.6% (n=221) placebo @ 2wk0.15% cream
NCT04773587 · Phase 3
14.3% (n=433) vs 5.9% (n=221) placebo @ 1wk0.15% cream
NCT04773587 · Phase 3
vIGA-AD 0 1 40.1% (n=439) @ 4wk0.15%
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT04804605 · Phase 3 · registry result, not featured evidence
show 19 more results
35.7% (n=219) @ 4wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
42.2% (n=439) @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
36.9% (n=219) @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
48.2% (n=439) @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
46.3% (n=219) @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
45.5% (n=439) @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
49.6% (n=219) @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
47.9% (n=439) @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
45% (n=219) @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
30.8% (n=439) @ 4wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
7.8% (n=219) @ 4wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
33.7% (n=439) @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
15.8% (n=219) @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
39.7% (n=439) @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
21.6% (n=219) @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
37.4% (n=439) @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
23.5% (n=219) @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
42.7% (n=439) @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
24.2% (n=219) @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
WI-NRS -2.1 score @ 4wk0.15%
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT04804605 · Phase 3 · registry result, not featured evidence
show 9 more results
-0.3 score @ 4wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-2.4 score @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-0.2 score @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-2.7 score @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-0.8 score @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-2.6 score @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-0.3 score @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-3.2 score @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-1.2 score @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
EASI -63.23% (n=439) @ 4wk0.15%
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
NCT04804605 · Phase 3 · registry result, not featured evidence
show 9 more results
-36.93% (n=219) @ 4wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-68.39% (n=439) @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-17.95% (n=219) @ 12wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-72.81% (n=439) @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-33.34% (n=219) @ 24wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-73.81% (n=439) @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-39.2% (n=219) @ 36wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-74.57% (n=439) @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
-27.94% (n=219) @ 52wk0.15%
NCT04804605 · Phase 3 · registry result, not featured evidence
EASI -6.03 vs -4.84 placebo score @ 4wk0.05%
absolute change · score
NCT03916081 · Phase 2 · registry result, not featured evidence
show 5 more results
-6.44 vs -4.84 placebo score @ 4wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
-3.11 vs -2.19 placebo score @ 1wk0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence
-2.77 vs -2.19 placebo score @ 1wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
-4.8 vs -4.31 placebo score @ 2wk0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence
-5.02 vs -4.31 placebo score @ 2wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
EASI-90 0% (n=46) vs 0% (n=45) placebo @ 1wk0.05%
responder rate · % of participants
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 5 more results
2.2% (n=45) vs 0% (n=45) placebo @ 1wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
2.2% (n=46) vs 8.9% (n=45) placebo @ 2wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
13.3% (n=45) vs 8.9% (n=45) placebo @ 2wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
17.4% (n=46) vs 17.8% (n=45) placebo @ 4wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
26.7% (n=45) vs 17.8% (n=45) placebo @ 4wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 12 Participants as posted
EASI 100 0% (n=46) vs 0% (n=45) placebo @ 1wk0.05%
responder rate · % of participants
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 5 more results
0% (n=45) vs 0% (n=45) placebo @ 1wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
2.2% (n=46) vs 0% (n=45) placebo @ 2wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
4.4% (n=45) vs 0% (n=45) placebo @ 2wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
2.2% (n=46) vs 2.2% (n=45) placebo @ 4wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
11.1% (n=45) vs 2.2% (n=45) placebo @ 4wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 5 Participants as posted
WI-NRS -2.21 vs -1.7 placebo score @ 1wk0.05%
absolute change · score
NCT03916081 · Phase 2 · registry result, not featured evidence
show 5 more results
-2.46 vs -1.7 placebo score @ 1wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
-2.46 vs -2.04 placebo score @ 2wk0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence
-2.76 vs -2.04 placebo score @ 2wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
-3.34 vs -2.73 placebo score @ 4wk0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence
-3.23 vs -2.73 placebo score @ 4wk0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence
WI-NRS 4 Improvement 23.9% (n=46) vs 20% (n=45) placebo @ 1wk0.05%
event count · % of participants
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
show 5 more results
33.3% (n=45) vs 20% (n=45) placebo @ 1wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted
21.7% (n=46) vs 35.6% (n=45) placebo @ 2wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
33.3% (n=45) vs 35.6% (n=45) placebo @ 2wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted
45.7% (n=46) vs 40% (n=45) placebo @ 4wk*0.05%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
37.8% (n=45) vs 40% (n=45) placebo @ 4wk*0.15%
NCT03916081 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted
Pruritus VAS -3.05 vs -1.5 placebo score @ 2.142857wk0.5%
absolute change · score
NCT01856764 · Phase 2 · registry result, not featured evidence

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: crisaborole's landscape · Roflumilast (Zoryve)'s landscape